Pfizer
PFE (NYSE)
With a robust dividend yield of 7.01%, Pfizer (PFE) stands out as a top-rated choice among S&P 500 stocks for income-focused investors. Despite its challenging 5-year return of -34.20%, the stock has delivered a solid 20.21% return over the past year, reflecting its potential for recovery. Analysts maintain a median price target of $28.50, with ratings ranging from Hold to Outperform, indicating a cautious yet optimistic outlook for this financially healthy pharmaceutical giant.
Pros:
- High dividend yield
- Positive 1-year return
Cons:
- Negative 5-year return
- Market volatility risk
Pfizer (PFE) may be suitable for income-focused investors seeking a high dividend yield, particularly those who are willing to navigate potential volatility given its mixed long-term performance. While the recent 1-year return suggests a positive recovery trend, prospective investors should consider their risk tolerance and investment horizon before adding this stock to their portfolios.